Investors & Media

Ionis reports fourth quarter and full year 2023 financial results

WAINUA™  approved with launch underway; on track for EU and Canada approval decisions this year Positive Phase 3 olezarsen and donidalorsen data, preparing regulatory submissions for FCS and HAE, respectively Olezarsen granted Breakthough Therapy designation by the FDA for FCS Ionis provides full

Read more
You are now leaving https://www.ionispharma.com to visit